PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid has announced an exclusive commercial partnership with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX₁₀₀, a drug designed to prevent surgical site infections. PolyPid stands to receive over $320 million in potential payments, including an initial $30 million upfront and near-term …